肿瘤药学2016，Vol.6Issue(2)：81-88,8.DOI:10.3969/j.issn.2095-1264.2016.02.01
小分子表皮生长因子受体酪氨酸激酶抑制剂的研究进展
Research Progress of Small-molecule Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
摘要
Abstract
Epidermal growth factor receptor (EGFR), a receptor on membrane surface, is over expressed in non-small cell lung cancer with tyrosine kinase activity. It plays an important role in proliferation, metastasis, metabolism, differentiation and survival of cells. Currently, the development of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has become a hot topic in the field of tumor therapy. According to the reversibility of binding with EGFR, the EGFR-TKIs can be classified into reversible and irreversible EGFR-TKIs. Reversible EGFR-TKIs include gefitinib, erlotinib and some others which are available in the market. Irreversible EGFR-TKIs involve afatinib and some novel antineoplastics which are still in clinical trials, including AZD9291, CO-1686 and HM61713. In this work, some latest researches about the development of EGFR-TKIs were reviewed for provide some information to non-small cell lung cancer therapies in clinic.关键词
抗肿瘤药物/表皮生长因子受体酪氨酸激酶抑制剂/非小细胞肺癌Key words
Antineoplastics/Epidermal growth factor receptor-tyrosine kinase inhibitors/Non-small cell lung cancer分类
医药卫生引用本文复制引用
李莹,田驰,王磊,谢蒙蒙,程泽能..小分子表皮生长因子受体酪氨酸激酶抑制剂的研究进展[J].肿瘤药学,2016,6(2):81-88,8.基金项目
国家自然科学基金资助项目（81573498）。 （）
